SEC Form 4 · accession 0001209191-15-077846
STERIS plc · STE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John P Wareham
Director
Period of report
Nov 2, 2015
Accepted (ET)
Nov 2, 2015 · 5:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001624899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, ?0.10 Nominal ValueF1 | Nov 2, 2015 | A | 31,560 | — | A | 31,560 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F2 | $31.61 | Nov 2, 2015 | A | 4,995 | A | — | Aug 3, 2021 | Ordinary Shares, ?0.10 Nominal Value | 4,995 | 4,995 | D |
| Director Stock Option (right to buy)F3 | $32.36 | Nov 2, 2015 | A | 5,150 | A | — | Aug 3, 2022 | Ordinary Shares, ?0.10 Nominal Value | 5,150 | 5,150 | D |
| Director Stock Option (right to buy)F4 | $43.92 | Nov 2, 2015 | A | 6,727 | A | — | Aug 8, 2023 | Ordinary Shares, ?0.10 Nominal Value | 6,727 | 6,727 | D |
| Director Stock Option (right to buy)F5 | $51.53 | Nov 2, 2015 | A | 6,622 | A | — | Aug 6, 2024 | Ordinary Shares, ?0.10 Nominal Value | 6,622 | 6,622 | D |
| Director Stock Option (right to buy)F6 | $64.05 | Nov 2, 2015 | A | 5,936 | A | — | Aug 31, 2025 | Ordinary Shares, ?0.10 Nominal Value | 5,936 | 5,936 | D |
| Career Restricted Stock UnitsF7 | — | Nov 2, 2015 | A | 5,633 | A | — | — | Ordinary Shares, ?0.10 Nominal Value | 5,633 | 5,633 | D |
Explanation of responses
- F1Represents ordinary shares of STERIS plc ("New STERIS") acquired pursuant to merger of a wholly-owned subsidiary of New STERIS with and into STERIS Corporation ("STERIS"), with STERIS surviving the merger as a wholly-owned subsidiary of New STERIS (the "Merger"), in exchange for common shares of STERIS, which was consummated simultaneous with and conditioned on New STERIS' acquisition of Synergy Health plc by commencing a "recommended offer" under English law. At the effective time of the Merger, each STERIS common share was cancelled and converted into the right to receive one New STERIS ordinary share.
- F2This option to purchase 4,995 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 4,995 STERIS common shares for $31.61 per share, subject to the same terms and conditions as the original STERIS stock option.
- F3This option to purchase 5,150 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 5,150 STERIS common shares for $32.36 per share, subject to the same terms and conditions as the original STERIS stock option.
- F4This option to purchase 6,727 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 6,727 STERIS common shares for $43.92 per share, subject to the same terms and conditions as the original STERIS stock option.
- F5This option to purchase 6,622 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 6,622 STERIS common shares for $51.53 per share, subject to the same terms and conditions as the original STERIS stock option.
- F6This option to purchase 5,936 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 5,936 STERIS common shares for $64.05 per share, subject to the same terms and conditions as the original STERIS stock option.
- F7At the effective time of the Merger, each STERIS career restricted stock unit was cancelled and converted to a New STERIS career restricted stock unit, subject to the same terms and conditions that were applicable to the original STERIS career restricted stock unit. These New STERIS career restricted stock units are fully vested and will be settled in New STERIS ordinary shares six months after the cessation of the Director's Board service.